Retatrutide in Combination With NAD+ and Peptide Therapies: Clinical Rationale and Practice Considerations

Clinic owners who are running retatrutide research programs are increasingly exploring combination protocols — pairing retatrutide with NAD+ therapy, supportive peptides, or other longevity-focused interventions. The clinical rationale for some of these combinations is compelling. The compliance considerations are significant. Here is how to think about both.

Retatrutide and NAD+

Retatrutide produces significant metabolic changes — rapid weight loss, improved insulin sensitivity, reduced inflammation. These changes place metabolic demands on cellular energy systems. NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme in cellular energy metabolism, and NAD+ levels decline with age and with metabolic stress.

The theoretical rationale for combining retatrutide with NAD+ supplementation is that supporting cellular energy metabolism during the rapid metabolic changes induced by retatrutide may improve tolerability, reduce fatigue, and support the preservation of lean muscle mass during weight loss. There is no direct clinical trial data on this combination, but the mechanistic rationale is reasonable and the safety profile of NAD+ supplementation is well-established.

Retatrutide and Muscle-Preserving Peptides

One of the clinical concerns with rapid weight loss from GLP compounds is the loss of lean muscle mass alongside fat mass. The TRIUMPH trial data shows that retatrutide produces significant fat mass reduction, but the muscle mass preservation data is less robust than what has been observed with some other approaches.

Peptides with anabolic or muscle-preserving properties — such as BPC-157, which has shown tissue repair and anti-inflammatory properties in preclinical research — are being explored as adjuncts to GLP programs to support lean mass preservation. The clinical evidence for these combinations is limited, but the theoretical rationale is driving significant clinical interest.

Retatrutide and Sermorelin/Growth Hormone Secretagogues

Growth hormone secretagogues like sermorelin stimulate endogenous growth hormone production, which supports lean muscle mass, fat metabolism, and recovery. Some clinic owners are combining retatrutide with sermorelin as part of a comprehensive metabolic optimization protocol for patients who are focused on body composition rather than weight loss alone.

IRB Protocol Scope

If your IRB protocol covers retatrutide administration, it covers retatrutide — not retatrutide plus NAD+, not retatrutide plus BPC-157. Adding additional compounds to the protocol requires an amendment. Administering additional investigational compounds to research subjects outside the scope of the approved protocol is a protocol deviation.

Before you add any compound to your retatrutide research protocol, consult with your IRB about whether an amendment is required. For compounds that are not investigational — NAD+ precursors that are available as dietary supplements, for example — the analysis may be different than for compounds that are themselves investigational.

Drug Interaction Documentation

When you are administering multiple compounds to a research subject, you are responsible for documenting the rationale for the combination and monitoring for potential interactions. The interaction profile of retatrutide with other compounds is not fully characterized. Document your clinical rationale for any combination approach and monitor patients carefully for unexpected effects.

Informed Consent for Combination Protocols

If your research subjects are receiving additional compounds alongside retatrutide, your informed consent document must disclose those compounds, their investigational status, and the known and unknown risks of the combination. A consent document that covers only retatrutide is not adequate for a combination protocol.

From a business perspective, combination protocols create an opportunity to increase the revenue per patient and the clinical value of your program. A patient who is receiving retatrutide plus NAD+ plus a muscle-preserving peptide is receiving a comprehensive metabolic optimization program — not just a weight loss injection. That program can be priced accordingly.

The key is ensuring that the compliance infrastructure keeps pace with the clinical complexity. A combination protocol that is not properly documented, not properly consented, and not properly monitored is a liability, not an asset. Build the compliance infrastructure first, then build the clinical program on top of it.

MedClinic Partners supplies 503A and 503B compounded GLPs, NAD+, and research-grade peptides through compliant channels. For clinic owners who are building combination protocols, we can discuss supply arrangements that cover the full range of compounds in your program — with the quality documentation required to support a defensible compliance position.